SG11202009791VA - Anti-pd-l1 antibody and use thereof - Google Patents

Anti-pd-l1 antibody and use thereof

Info

Publication number
SG11202009791VA
SG11202009791VA SG11202009791VA SG11202009791VA SG11202009791VA SG 11202009791V A SG11202009791V A SG 11202009791VA SG 11202009791V A SG11202009791V A SG 11202009791VA SG 11202009791V A SG11202009791V A SG 11202009791VA SG 11202009791V A SG11202009791V A SG 11202009791VA
Authority
SG
Singapore
Prior art keywords
antibody
Prior art date
Application number
SG11202009791VA
Inventor
Bohua Li
Huajing Wang
Xiaowen He
Original Assignee
Origincell Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origincell Therapeutics Co Ltd filed Critical Origincell Therapeutics Co Ltd
Publication of SG11202009791VA publication Critical patent/SG11202009791VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202009791VA 2018-04-09 2018-08-27 Anti-pd-l1 antibody and use thereof SG11202009791VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810309302 2018-04-09
PCT/CN2018/102584 WO2019196309A1 (en) 2018-04-09 2018-08-27 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
SG11202009791VA true SG11202009791VA (en) 2020-11-27

Family

ID=68163043

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009791VA SG11202009791VA (en) 2018-04-09 2018-08-27 Anti-pd-l1 antibody and use thereof

Country Status (17)

Country Link
US (1) US20210380698A1 (en)
EP (1) EP3778635A4 (en)
JP (2) JP7360720B2 (en)
KR (1) KR20200140882A (en)
CN (4) CN113087799B (en)
AU (1) AU2018418224A1 (en)
BR (1) BR112020020637A2 (en)
CA (1) CA3095498A1 (en)
CL (1) CL2020002600A1 (en)
CO (1) CO2020013833A2 (en)
EA (1) EA202092420A1 (en)
IL (2) IL297847B2 (en)
MX (1) MX2020010653A (en)
PH (1) PH12020551661A1 (en)
SG (1) SG11202009791VA (en)
WO (1) WO2019196309A1 (en)
ZA (1) ZA202006255B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199447A1 (en) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
JP2024503393A (en) * 2021-01-08 2024-01-25 北京韓美薬品有限公司 Anti-PD-L1/anti-4-1BB natural antibody structure-like heterodimer bispecific antibody and method for producing the same
WO2023000675A1 (en) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 Bispecific antibody targeting pd-l1 and 4-1bb
WO2023134657A1 (en) * 2022-01-11 2023-07-20 原启生物科技(上海)有限责任公司 Anti-cldn18.2 and 4-1bb bispecific antigen binding protein and use thereof
WO2023138638A1 (en) * 2022-01-24 2023-07-27 原启生物科技(上海)有限责任公司 Bispecific antigen-binding protein against tigit and pd-l1 and use thereof
CN114736303A (en) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 Bifunctional antibody for resisting PD-L1 and 4-1BB and medical application thereof
CN116120461B (en) * 2022-04-29 2023-09-29 德琪(杭州)生物有限公司 Novel anti-drug antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
DK1907424T3 (en) * 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AU2013326901B2 (en) * 2012-10-04 2018-05-31 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-PD-L1 antibodies and methods of use
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CN105017421B (en) * 2014-04-16 2017-12-26 中国人民解放军海军总医院 A kind of anti-HER2 bispecific antibodies and preparation method and application
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
CN105669862A (en) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 Anti-human PD-L1/KIR bispecific antibody, preparation method and application thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN105777906B (en) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 Anti- PD-L1 human antibody and its application
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
CA2989586A1 (en) * 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CN106939047B (en) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
CN116333124A (en) * 2016-01-29 2023-06-27 索伦托药业有限公司 Antigen binding proteins that bind to PD-L1
KR20190079713A (en) * 2016-06-13 2019-07-05 아이-맵 Anti-pd-l1 antibodies and uses thereof
CN107488229B (en) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 PD-L1 antibodies and uses thereof
IL296127A (en) * 2016-07-22 2022-11-01 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
JOP20190009A1 (en) * 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
EP4342912A2 (en) 2016-09-23 2024-03-27 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CN106699891B (en) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 A kind of anti-PD-L1 antibody, its medical composition and its use
CN107298713B (en) * 2017-08-15 2019-12-06 联合益康（北京）生物科技有限公司 anti-PD-L1 antibody, application, preparation method, kit and medicament

Also Published As

Publication number Publication date
IL297847A (en) 2023-01-01
MX2020010653A (en) 2020-10-28
US20210380698A1 (en) 2021-12-09
IL297847B1 (en) 2023-10-01
BR112020020637A2 (en) 2021-03-23
EP3778635A1 (en) 2021-02-17
CA3095498A1 (en) 2019-10-17
JP7360720B2 (en) 2023-10-13
WO2019196309A1 (en) 2019-10-17
ZA202006255B (en) 2022-03-30
KR20200140882A (en) 2020-12-16
CN115991778A (en) 2023-04-21
CN110869390A (en) 2020-03-06
EA202092420A1 (en) 2021-01-28
JP2021530430A (en) 2021-11-11
AU2018418224A1 (en) 2020-11-26
CN110869390B (en) 2021-05-11
CL2020002600A1 (en) 2021-01-29
CO2020013833A2 (en) 2020-12-21
CN113121698A (en) 2021-07-16
PH12020551661A1 (en) 2021-06-07
CN113087799B (en) 2023-03-31
JP2023179558A (en) 2023-12-19
IL277893A (en) 2020-11-30
CN113121698B (en) 2022-11-01
EP3778635A4 (en) 2022-01-26
CN113087799A (en) 2021-07-09
IL297847B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL273411A (en) Anti-pd-l1 antibody and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL278846A (en) Anti-cd3 antibodies and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL279455A (en) Anti-pd-1 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
EP3612565A4 (en) Anti-pd-l1 antibody and use thereof
IL268051A (en) Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
IL274564A (en) Anti-pd-l1 antibody and il-7 fusions
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL265485A (en) Diagnostic anti-pd-l1 antibody and use thereof
IL285569A (en) Anti-pd-l1 antibody and use thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
EP4032904A4 (en) Anti-alpha-hemolysin antibody and use thereof
IL276675A (en) Anti-pd-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof